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P
atient engagement is increasingly regarded as critical to maximizing the value of medical research. In the United States, the growing emphasis on engagement is reflected by the founding of the Patient-Centered Outcomes Research Institute (PCORI) as well as initiatives spearheaded by the Institute of Medicine and the U.S. Food and Drug Administration (FDA) to grant patients' perspectives a central role in determining research priorities and informing the design and conduct of clinical trials (1) (2) (3) . Such initiatives, often captured under the rubric of patient-centered outcomes research (PCOR), are characterized by a commitment to incorporating patient perspectives at every stage of research and promoting patient involvement in key study roles.
Although attempts to define PCOR and distinguish it from other forms of clinical research are sometimes amorphous (4), PCORI, the leading funder of PCOR, describes its mandate as "improv[ing] the quality and relevance of evidence available to help patients, caregivers, clinicians, employers, insurers, and policy makers make better-informed health decisions. To do this, we work with those healthcare stakeholders to identify critical research questions and answer them through comparative clinical effectiveness research . . . focusing on outcomes important to patients" (5). Thus, PCORI departs from the traditional clinical research paradigm, in which investigators drive the conceptualization and implementation of research, and embraces an approach in which patients are involved throughout the life cycle of research projects-"from proposal development to research design and dissemination of the study results" (6, 7) . The 21st Century Cures Act, passed in 2016, echoes this approach, acknowledging that patients are "in a unique position to contribute to an understanding of benefit and risk considerations throughout the medical product development process" and recognizing "the need for systematic collection of direct patient input" to guide choices about drug development (8) . The underlying assumption of these efforts is that "research meaningfully informed by the patient perspective is more likely to be used to inform patient decision-making and, in the end, to improve patient outcomes" (6) .
However, primarily as the result of engaging patients in roles other than research subject, PCOR raises novel ethical and regulatory issues and exacerbates some familiar ones, such as challenges associated with emerging technologies, whose use in PCOR may be more prevalent than in traditional clinical research (9) . Despite notable efforts to promote and facilitate the conduct of PCOR, scant attention has been paid to these oversight challenges (10 -12) . (The exception is the debate around standards for risk assessment and informed consent in comparative effectiveness research in the wake of the controversy surrounding SUPPORT [Surfactant, Positive Pressure, and Oxygenation Randomized Trial] [13, 14] . Given the attention those issues have already received, the research team decided to focus on less-explored oversight challenges with PCOR.) Indeed, there exists no formal regulatory or ethics guidance on oversight of PCOR from the FDA, the Department of Health and Human Services Office for Human Research Protections, or other regulatory bodies. In this article, we address this gap and share policy recommendations derived through a modified Delphi consensus process.
METHODS
These recommendations are the product of PCOROS (Patient-Centered Outcomes Research Oversight Study), a multiphase, mixed-methods research project funded by PCORI (ME-1409-21701). In phases 1 and 2, the PCOROS team engaged key stakeholders through individual interviews, case studies, and focus groups and administered a survey to institutional review board (IRB) chairs at all major U.S. research insti-tutions (7, 8) . Three domains were found to merit further guidance: 1) oversight of patients in nontraditional research roles, such as co-investigator, study personnel, or advisor; 2) emerging technologies (such as social media or mobile applications), whose use as part of study design in PCOR seems to be more common and larger in scale than in traditional research; and 3) effective identification of patient research partners and mitigation of conflicts of interest.
To generate recommendations that address these areas of need, we then employed a modified Delphi process, which uses multiple rounds of evaluation to gauge and facilitate consensus among a group of expert stakeholders on a particular topic (15) (16) (17) (18) . The Delphi technique was chosen because it is recognized as an optimal method for consensus building, with use of anonymous feedback from an expert panel and statistical analysis techniques to interpret the data. The iterative nature of the process avoids some of the pitfalls of other methods, such as the effects of dominant persons or the tendency to conform to a particular viewpoint. A full list of panel participants is provided in Appendix 1 (available at Annals.org), and an explanation of the modified Delphi technique and a more detailed description of the process we used is given in Appendix 2 (available at Annals.org).
RECOMMENDATIONS
Twenty-one recommendations for PCOR oversight met the prespecified criteria for consensus via the Delphi process (Table) . We summarize them here, organized by the 3 domains identified earlier.
Domain 1: Recommendations Addressing Patients and Other Stakeholders (Such as Patient Advocates or Caregivers) in Nontraditional Study Roles
The panel endorsed 10 recommendations addressing oversight of PCOR involving patients in roles other than research subject. These recommendations include guidance on classifying patient research partners according to a formal taxonomy of research roles, appropriate ethics and scientific training for patients in nontraditional roles, the permissibility of patients occupying multiple research roles simultaneously and switching between roles in the same study, and providing compensation to patient research partners (see domain 1 in the Table) .
Domain 2: Recommendations Addressing Oversight of Emerging Technologies in PCOR
Although the oversight challenges posed by emerging technologies, such as mobile applications and social media, are not unique to PCOR given that these technologies are also used in other types of research, the relative prevalence of these technologies in PCOR was identified in interviews and the survey of IRB chairs as sufficiently important to address in this context (6, 9, 19) . The Delphi panel achieved consensus on 6 recommendations addressing this domain. The endorsed recommendations include guidance on educating PCOR stakeholders about protecting participant privacy and confidentiality when using emerging technologies, best practices for data collection using emerging technologies, protections around use of social media in recruitment efforts, and use of electronic platforms for obtaining consent in PCOR studies (see domain 2 in the Table) .
Domain 3: Recommendations Addressing Identification and Engagement of Patient Partners
The Delphi panel achieved consensus on 5 recommendations addressing the identification and engagement of patient research partners. These address the need for education of investigators and sponsors in identifying and selecting potential research partners, the importance of achieving a diverse mix of patient voices in PCOR, the need for education on identifying and mitigating financial and nonfinancial conflicts of interest among patient research partners, and advice to IRBs on how to approach financial conflicts of interest among patient partners occupying study personnel roles (see domain 3 in the Table) .
DISCUSSION
The most novel oversight challenge posed by PCOR concerns the standards that should be applied to persons occupying nontraditional research roles, which is addressed by our first domain of recommendations. This is particularly important when patients fill roles other than research subject. In this case, there is tension between the need for IRBs to provide effective oversight for patients in study roles typically filled by traditional researchers and research staff and refraining from unnecessarily exceptionalizing patients by treating them differently from others in these roles without adequate reason. Although patients may benefit from training and education tailored specifically to their needs, they should not be held to different standards or treated differently from other study team members serving in similar roles. Indeed, there is evidence that IRBs can be overprotective of patient research partners by applying human subjects protections to them, such as informed consent, even when they are not enrolled as research subjects (9) .
Disambiguating the various roles that patients may fill in PCOR will bring needed clarity. To address this, the recommendations endorse a formal taxonomy of patient involvement in research (recommendations 1 to 5) that distinguishes 3 broad roles patients might occupy-study personnel, advisor, and research subject-and whose main purpose is to allow IRBs to determine adequate protections and training requirements for patients depending on the role and activities they assume, bringing greater uniformity to practice. This taxonomy is complemented by recommendation 9, which clarifies that oversight protections should not be applied to patients involved in research unless they meet the regulatory definition of "research subject," thereby guarding against overprotection.
At the same time, the role of patient partners in PCOR studies may be fluid. Such studies may be more likely than traditional clinical research to involve patients occupying multiple roles (for example, research subject and study personnel) and switching between roles (for example, from subject to advisor) in the same study, which raises oversight challenges (6, 9) . Although there may be value in leveraging patients' perspectives on different aspects of the research, caution should endorse and make available educational modules aimed at facilitating and improving the ability of patients and other stakeholders to serve effectively in study personnel roles, providing guidance on ethical, scientific/methodological, and logistical challenges that they may encounter. Recommendation 6: Principal investigators should not invite and IRBs should not permit patients and other stakeholders to occupy the research subject and study personnel roles simultaneously in the same study because of concerns about scientific integrity (e.g., the potential for unblinding or other forms of bias) and potential conflicts of commitment for these persons (e.g., if the person's own interests as a patient were to conflict with the aims of research). However, in exceptional circumstances (such as when significant research would otherwise be impracticable), the IRB may consider permitting the practice after consulting with relevant institutional officials and developing adequate protections appropriate to the circumstances. Recommendation 7: Principal investigators should take precautions when inviting patients and other stakeholders to occupy the research subject and advisor roles simultaneously in the same study because of potential conflicts of commitment for these persons (e.g., if the person's own interests as a patient were to conflict with the aims of research). These precautions might include notifying and consulting with the IRB on appropriate safeguards. Recommendation 8: Principal investigators may invite and IRBs should permit patients and other stakeholders to switch from the research subject role to a study personnel or advisor role in the same study once their active participation is complete, provided that steps are taken to avoid conflicts and inappropriate incentives for patients and other stakeholders while occupying the research subject role (such as might occur if the prospect of earning advising fees once participation is complete were to inappropriately motivate one to enroll or remain in a study). Recommendation 9: IRBs should not require informed consent or the application of other relevant human subjects protections for patients and other stakeholders in research roles who do not satisfy the regulatory definition of "research subject." Recommendation 10: Principal investigators should establish clear expectations with patients and other stakeholders who are study personnel and advisors on remuneration and other potential benefits of involvement (e.g., authorship) and compensate them in ways that fairly acknowledge their time and contribution to the project in accordance with PCORI's compensation framework (www.pcori.org/sites/default/files/PCORI-CompensationFramework-for-Engaged-Research-Partners.pdf).
Table-Continued
Domain 2: Oversight of emerging technologies in PCOR Recommendation 11: Because of the prevalence of emerging technologies in PCOR, PCORI (or other relevant funding or regulatory agencies) should develop training modules aimed at educating researchers, patient research partners, and IRB members on common emerging technology platforms (e.g., Twitter and Fitbit) and the ethical and regulatory issues associated with them. Recommendation 12: PCOR investigators should clearly indicate to the IRB which emerging technologies will be used (e.g., social media platforms, mobile applications, and wearable devices) as part of normal protocol development and submission. Recommendation 13: For PCOR recruitment efforts involving social media and/or mobile applications, investigators should submit a statement to the IRB detailing how study personnel will identify potential research subjects and maintain their privacy and a communication plan for managing interactions between study staff and potential subjects. Recommendation 14: For PCOR studies that plan to obtain consent from subjects remotely using electronic media, investigators and sponsors should clearly articulate a plan for confirming the identity of subjects and answering prospective subjects' questions about the study in line with regulatory guidance (www.fda.gov/ downloads/drugs/guidances/ucm436811.pdf). Exceptions may be possible for minimal-risk research. Recommendation 15: For studies that plan to collect data by using emerging technologies, investigators should submit a statement to the IRB detailing measures to safeguard privacy and confidentiality, addressing such issues as who will have access to the data and safeguards around inadvertent collection of data unrelated to the study aims. Recommendation 16: PCORI (or another funding, regulatory, or policymaking body) should develop consensus best practices for addressing the ethical and legal implications associated with data collection using emerging technologies. is needed to prevent conflicts between roles and to safeguard scientific integrity. Problems might arise, for example, if patients are both research subjects and personnel in the same study; their obligations as study personnel to ensure scientific integrity (including maintenance of a blind and the use of randomization and placebo) may conflict with their interests as patientsubjects in knowing which intervention they are receiving and being treated for their medical condition. Recommendations 6 to 8 provide actionable guidance for how IRBs and investigators should approach these situations.
In addition, although oversight bodies are used to evaluating and managing researchers' conflicts of interest, they may be less familiar with recent empirical evidence of strong financial connections between industry and certain patient advocacy groups, which may give rise to conflicts of interest for patient partners (20, 21) . Another challenge is making sure that investigators receive input from a diverse set of patients in research design and implementation. Recommendations 17 to 21 address these issues, rejecting the high bar of patient partners being "representative" of the population from which they come and instead recommending that investigators cultivate a diverse mix of patient partners. Further, these recommendations call for guidance from a high-level policy body, such as PCORI, on identifying and managing conflicts of interest among patient partners.
CONCLUSION
For PCOR to realize its full potential to yield knowledge that is valuable to patient decision making, the ethical and regulatory oversight challenges it raises must be met systematically and with confidence and transparency that will inspire trust in the research enterprise. Issues of PCOR oversight can sometimes be complex, and IRBs often differ in their interpretations of the relevant regulatory concepts and ethical issues. Consensus among content matter experts from diverse PCOR stakeholder groups provides a solid basis for adopting recommendations that can help clarify challenging aspects of PCOR oversight. The policy recommendations advanced here, which target IRBs, investigators, and high-level funding and regulatory bodies, set an agenda for immediate implementation as well as additional study to address areas of need in PCOR oversight and bring uniformity to practice. Such implementation would ideally be carried out by PCORI or other high-level policy bodies. 
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